Study guide
19.2 Monitoring Plans, Co-Monitoring and Communication
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
19.2 Monitoring Plans, Co-Monitoring and Communication
Key Takeaways Explain This Topic AI
A monitoring plan links risks to methods, responsibilities, timing and follow-up.
Co-monitoring needs a clear purpose and coordinated access and communication.
Important decisions and action ownership should remain traceable across communication channels.
Last updated: October 2026
Monitoring Plans, Co-Monitoring and Communication
A monitoring plan should explain how the sponsor will obtain adequate assurance about participant protection, protocol conduct and reliable results. E6(R3) supports risk-proportionate monitoring that can combine site, remote and central activities. A plan is more than a visit calendar or an instruction to verify every field. It connects important risks to methods, responsibilities, timing, review and follow-up.
Identify critical data and processes, why errors would matter and which controls can detect or prevent them. Consider the trial's purpose, design, population, product, complexity, systems and endpoints. The strategy should be justified and adaptable as evidence accumulates. A low visit count is not proof of weak oversight, and frequent travel is not proof of adequate oversight.
What a usable plan addresses
Who performs site, remote and central activities and how findings are exchanged.
Which data/processes receive review and the rationale for coverage.
Planned timing and triggers for additional or different activities.
Access, confidentiality and blinding controls.
Documentation, sponsor review, escalation and issue follow-up.
How significant changes in risk or performance lead to reassessment.
No universal ICH rule prescribes 100% consent/eligibility SDV, the first three participants or a fixed percentage of low-risk data. Such requirements can be part of a particular justified plan. The underlying obligations still apply to every participant: consent, appropriate care, protocol compliance and reliable records. A monitoring sample does not authorise unsampled participants to receive lower standards.
Combining methods
Central review can detect cross-site trends, missing data, implausible patterns and important delays. Remote site monitoring can review appropriate systems/records and follow up specific issues. On-site activity can examine physical storage, facilities and source context that is difficult to assess remotely. The mix should fit the information needed and available controls.
A central signal should reach the people able to investigate it. If a site reports no AEs after substantial exposure, check whether data are current, the population/exposure differs or the collection process failed. Source review and investigator discussion may be needed. Do not automatically generate fictitious events or label the site fraudulent. Conversely, do not congratulate it solely because a dashboard looks clean.
Co-monitoring and training visits
The ECO tasks include co-monitoring and training visits. These can help evaluate or develop monitoring performance, support consistency or address a particular issue. Clarify the purpose, participants, authority and documentation in advance. Two monitors at a site should not duplicate queries, give contradictory instructions or broaden access beyond what is authorised.
A co-monitor may observe preparation, source review, prioritisation, communication and reporting. Feedback should identify evidence and an actionable development need. If a safety concern emerges, use the usual urgent route; do not postpone it until a training debrief. Any finding affecting trial conduct should reach the appropriate sponsor/site process, even if the visit also evaluates a monitor's skill.
Documenting important communication
A phone call, email, meeting or portal message can contain a consequential decision. Record the trial/site context, date, participants, issue, evidence, decision, action owner and due date as appropriate. Preserve relevant correspondence so a later reviewer can reconstruct what was communicated and whether it was followed. A casual statement remembered weeks later is weak evidence for a critical instruction.
- Communication Key distinction Follow-up
- Proposed solution Not yet an approved trial change Obtain required evaluation/authorisation
Urgent safety notification Needs timely clinical/operational action Confirm receipt and action through the designated route
- Routine monitoring finding Requires evidence-based resolution Track owner, deadline and completion evidence
- System defect May affect multiple sites or data streams Involve responsible technical/quality functions
- Training feedback Develops competence Verify the skill/process improvement
- Reports and site feedback
Monitoring documentation should communicate what was reviewed, significant findings, conclusions and actions taken or recommended, under the plan and procedures. Sponsor review should support appropriate oversight and follow-up. A site communication should provide the information needed to correct relevant findings. The specific document names and reporting deadlines come from the trial/organisation; ICH does not prescribe a universal five-day report and fifteen-day letter.
A monitoring report and follow-up letter can serve different audiences. Avoid copying confidential internal information or unnecessary participant identifiers into broadly distributed correspondence. Clear factual wording is more useful than accusatory language. Distinguish a confirmed deviation, a question awaiting evidence and an action already completed.
Reassessing the strategy
If problems recur, evaluate whether the original methods detect the important failure. Increasing SDV alone may not solve a missed safety-alert process or poor investigator oversight. Modify monitoring and other controls through the documented process, coordinate affected functions and verify effectiveness. Preserve the rationale for both the initial strategy and its change so the trial's quality approach can be understood at reporting and inspection.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .